HIV infection significantly decreases survival among women with invasive cervical cancer, according to a study conducted in Botswana. This was the case even though most women with HIV received antiretroviral therapy.
In this interview we discuss a joint statement from MD Anderson and 68 other NCI-designated cancer centers that calls for increased HPV vaccination for the prevention of cancer.
A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.
A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
Testing for HPV infections in urine could be an extremely accurate way to exclude the possibility of such infections and screen for cervical cancer.
ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.
Women who do not engage in regular physical activity have an increased risk of developing cervical cancer, according to a new study
The American Society of Clinical Oncology released a statement calling for the rapid expansion of use of the human papillomavirus (HPV) vaccine to help protect thousands of people from HPV-associated cancers.
In this review, we will summarize clinical trials that have used various immunotherapeutic strategies, with a particular focus on recently emerging data for new agents and combinations.
Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.